In the plenary discussion, facilitated by JPMA's Vision for 2035 Managing Director Yoshiyuki Ishida, each of the 16 committees shared their key initiatives in the action plan based on the three pillars (Innovation/Access/Trust) of JPMA's Vision for 2035, and had a lively discussion on the possibilities of co-creation. Lively discussions were also held on the possibility of co-creation.

Innovation

• - R & D Committee
  proposes the use of technology from academia. Presenting TPPs (Target Product Profiles) of pharmaceutical companies to strengthen collaboration.
• - Drug Evaluation Committee
  Emphasizes the importance of clinical trials. Proposes strengthening the evaluation system as the core of the drug discovery ecosystem.
• - Intellectual Property Committee
  Aims to strengthen IP strategies, including establishing an innovation promotion task force and legislating a data protection system.
• - Biopharmaceutical Committee
  Raised the issue of "human resources and materials" for the development of a domestic production system. Shows the need for collaboration from drug discovery to production.
• - Quality & Technology Committee/ICH Project
  Promotes international regulatory harmonization. Aiming to eliminate drug lag and loss by reviewing "Japan's own rules.
• - Pharmaceutical Industrial Policy Committee
  Co-creation with other committees has begun in a number of task forces that already exist. The committee's unique areas include policy recommendations related to the NHI drug pricing system and taxation system.

Access

• - International Affairs Committee
  Emphasizes the importance of reaching out to foreign authorities. Promotes efforts to improve global access.
• - Regulatory Affairs Committee
  Based on its experience working with the MHLW, the committee talks about the importance of co-creation, which has already begun. Aim to contribute to institutional design.
• - Distribution Improvement Committee
  Positioning drug pricing and distribution as "two wheels of a car," the committee will work with the Pharmaceutical Industrial Policy Committee to resolve issues related to stable supply and the pricing system.

Trust

• - Review Board of Ethical Drug Product Information Brochure/Code Compliance Committee
  Pledges to ensure proper promotion and provision of information based on "Trust.
• - Environmental Issue Committee
  Calls for co-creation with all committees to achieve carbon neutrality. Aiming to build trust as a sustainable industry.
• - Public Affairs Committee
  Shared the mission to inform the public that the pharmaceutical industry is an attractive core industry. Contributes to building trust with society.
• - Consumer Consultation Review Committee
  The last bastion of providing accurate and fair pharmaceutical information. Examines issues that arise as inquiries become more complex, develops countermeasures and makes recommendations.
• - Patient Cooperation Committee
  The committee will work with patient groups to build win-win relationships regarding access to clinical trial information and the way information should be provided.

The overall network became more visible. It was a time for all participants to reaffirm that collaboration beyond committee walls is the key to achieving the vision.